BCR-ABL-negative chronic myeloid leukemia

被引：4
作者：
Burgstaller S. [1 ]
Reiter A. [1 ]
Cross N.C.P. [1 ]
机构：
[1] Wessex Regional Genetics Laboratory, University of Southampton, Salisbury NHS Foundation Trust
来源：
Current Hematologic Malignancy Reports | 2007年 / 2卷 / 2期
关键词：
Imatinib; Chronic Myeloid Leukemia; Polycythemia Vera; Myeloproliferative Disorder; Systemic Mastocytosis;
D O I：
10.1007/s11899-007-0011-5
中图分类号：
学科分类号：
摘要：
Constitutive activation of protein tyrosine kinases plays a central role in the pathogenesis of myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukemia. Current research is focused on elucidating the full spectrum of causative mutations in this rare, heterogeneous disease. Activated tyrosine kinases are excellent targets for signal transduction therapy, and an accurate diagnosis including morphology, karyotyping, and molecular genetics will become increasingly important to direct individualized treatment. In addition, new molecular findings need to be incorporated into disease classification systems. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：75 / 82
页数：7
相关论文
共 75 条
[11]  
Score J., Curtis C., Waghorn K., Et al., Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia, Leukemia, 20, pp. 827-832, (2006)
[12]  
Pardanani A., Ketterling R.P., Li C.Y., Et al., FIP1L1-PDGFRA in eosinophilic disorders: Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature, Leuk Res, 30, pp. 965-970, (2006)
[13]  
Walz C., Curtis C., Schnittger S., Et al., Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9
[14]  
4)(q33
[15]  
q12q25) and a CDK5RAP2-PDGFRA fusion gene, Genes Chromosomes Cancer, 45, pp. 950-956, (2006)
[16]  
Wilkinson K., Velloso E.R., Lopes L.F., Et al., Cloning of the t(1
[17]  
5)(q23
[18]  
q33) in a myeloproliferative disorder associated with eosinophilia: Involvement of PDGFRB and response to imatinib, Blood, 102, pp. 4187-4190, (2003)
[19]  
Morerio C., Acquila M., Rosanda C., Et al., HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5
[20]  
17)(q33
12345678